Background: The present post hoc analysis investigated whether changes in endogenous glucagon-like peptide-1 (ΔGLP-1) levels are associated with weight loss in newly diagnosed diabetes patients. Methods: In all, 784 subjects from the Metformin and AcaRbose in Chinese as initial Hypoglycemic treatment (MARCH) study were stratified according to ΔGLP-1. Changes in clinical and physiological parameters were evaluated across ΔGLP-1 subgroups (low, medium, and high) to assess correlations between ΔGLP-1 and weight loss in acarbose-versus metformin-treated groups. Results: After 24 weeks treatment, greater ΔGLP-1 was associated with significantly greater weight loss (−2 vs −1 kg in the medium/high vs low ΔGLP-1 groups, respectively) and reduction in body mass index (BMI; −0.88, −0.83, and −0.69 kg/m 2 in the high, medium, and low ΔGLP-1 groups, respectively). In the acarbose-treated group, there was a significant association between ΔGLP-1 and BMI reductions, and greater ΔGLP-1 across the high, medium, and low ΔGLP-1 groups was correlated with greater weight loss (−2.8, −2.1, and −1.9 kg, respectively) and reductions in fasting plasma glucose (−1.57, −1.28, and −1.02 mmol/L, respectively) at Week 24. No significant differences were found across ΔGLP-1 subgroups in metformin-treated patients (P > 0.05). Multivariate linear regression analysis revealed that gender, baseline BMI, and ΔGLP-1 at Week 24 were associated with weight loss. Baseline BMI and ΔGLP-1 in the acarbose-treated group and baseline BMI in the metformin-treated group predicted weight loss at Week 24. Conclusion: Changes in GLP-1 levels are associated with weight loss in newly diagnosed Chinese diabetes patients receiving acarbose.
Introduction
Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance and progressive loss of β-cell function. 1 Being overweight or obese can increase the risk of cardiovascular disease in patients with T2D. 2 Achieving good weight control is a critical component of managing diabetes, especially because some antidiabetic agents (i.e. insulin, thiazolidinediones, and sulfonylureas) have the unwanted side effect of promoting weight gain. 2 Metformin and α-glucosidase inhibitors (AGIs) are used to treat T2D. Metformin is recommended as a first-line treatment drug because of its cardiovascular benefit and association with weight loss. 3, 4 Both metformin and AGIs, such as acarbose, miglitol, vitagliptin, and liraglutide, are associated with weight reduction or are weight neutral. [5] [6] [7] [8] [9] [10] [11] [12] The Metformin and AcaRbose in Chinese as the initial Hypoglycemic treatment (MARCH) study was a 48-week, randomized, controlled, non-inferiority, multicenter trial that included 788 patients newly diagnosed with T2D. 12 The purpose of the study was to evaluate the glucose-lowering effect of different drugs on T2D. The MARCH study found that after 24 weeks treatment, HbA1c reductions from baseline were −1.17% and −1.19% in the acarbose-and metformin-treated groups, respectively. 12 A progressive decrease in body weight in both treatment groups was also observed, although patients receiving acarbose had lost more weight than those receiving metformin at Week 24 (−0.67 kg; P = 0 Á 0054) and at Week 48 (−0.63 kg; P = 0 Á 0194). 12 The results of the MARCH study suggest that acarbose and metformin have similar efficacy with regard to glucose control and weight loss in Chinese patients with T2D. However, a significant association between glucose control and weight reduction was not observed.
The MARCH study measured levels of glucagon-like peptide (GLP-1) at baseline and at Weeks 24 and 48 after acarbose and metformin treatment, and found that both metformin and acarbose increased GLP-1 concentrations. 12 Glucagon-like peptide-1 is a proglucagon-derived peptide that improves glucose homeostasis by enhancing glucose-dependent insulin secretion, inhibiting inappropriately high levels of postprandial glucagon secretion, delaying gastric emptying, and reducing food intake. [13] [14] [15] [16] Prior studies indicate that GLP-1 receptor agonists are associated with greater weight loss in patients with T2D compared with traditional hypoglycemic drugs. 17 These findings raise the possibility that patients with increased GLP-1 levels may lose more weight compared with patients who have lower GLP-1 levels.
Although the main focus of the MARCH study was not the association between drugs and weight change, the effect of treatment on weight was of interest because, in recent years, an increasing number of studies has found that treatment-related weight reduction in patients with diabetes is independent of treatment effect on glycemic control. 18, 19 The present descriptive subanalysis of the MARCH trial investigated whether changes in GLP-1 levels from baseline after 24 and 48 weeks treatment were associated with weight reduction, and which other factors may be associated with weight. The present study was a novel study conducted to investigate the effects of acarbose and metformin after 24 and 48 weeks treatment on weight reduction, which involved regulation of GLP-1 levels, in T2D using data from the MARCH trial, the first head-to-head clinical trial of its type with a larger sample size.
Methods

Study participants and study design
The present study was a subgroup analysis of data from the MARCH trial 12 to evaluate whether changes in GLP-1 levels from baseline after 48 weeks treatment with acarbose or metformin affected weight loss in patients newly diagnosed with T2D.
In all, 788 patients newly diagnosed with T2D aged between 30 and 70 years, from 11 clinical sites in China, were enrolled in the non-inferiority, multicenter, randomized controlled MARCH trial. 12 Patients had been diagnosed with T2D within the previous 12 months according to the 1999 World Health Organization (WHO) criteria. 20 Patients with a history of renal disease, hematologic disease, severe gastrointestinal diseases, and cardiac, respiratory, or hepatic diseases were excluded, as were pregnant or breastfeeding women, those with mental disorders or those who had participated in a clinical trial within the previous 6 months. Data for the 784 patients who were finally included in the MARCH trial were evaluated in the present post hoc analysis.
Ethical considerations
The protocol of the original MARCH study (Chinese Clinical Trial Registry no. ChiCTR-TRC-08000231) 12 was approved by the appropriate ethics committees of the 11 Chinese clinical sites that participated in the study. All patients enrolled in the original MARCH study 12 provided signed informed consent.
Procedures
A detailed description of the MARCH trial methods has been published previously, 12 as have details of a follow-up study. 21 Briefly, in the original study, following a 4-week run-in period, patients with newly diagnosed T2D were randomly assigned to receive 1500 mg metformin hydrochloride (Double Crane Pharma, Beijing, China) once daily or up to 300 mg/day acarbose (up to 100 mg three times daily; Bayer Healthcare, Beijing, China) over a 24-week treatment period and, as necessary, as 24-week add-on treatment with insulin secretagogs.
During the 4-week screening and run-in phase, patients received education about therapeutic lifestyle modifications, according to the Chinese Guideline for the Prevention and Treatment of Diabetes Mellitus (2004). 22 Dietary education was provided by trained dietitians and total daily calories were calculated based on standardized body weight and labor intensity. Patients were asked to perform 30 min moderate exercise each day, such as brisk walking, jogging, cycling, or swimming). Clinic visits were scheduled in the first 4 weeks to occur every 2 weeks and from then on every 4 weeks.
Acarbose administration started at 50 mg once daily at dinner in the first week and was titrated up to 50 mg twice day (lunch and dinner) in the second week, 50 mg three times daily (at each meal) in the third week, and 100 mg three times daily from Week 4 onward. Metformin administration started at 500 mg once daily after dinner for the first 2 weeks and was then titrated to 1000 mg once daily after dinner in Week 3 and 1500 mg once daily after dinner from Week 4 onward.
The primary endpoint was reduction in HbA1c at 24 and 48 weeks. Key secondary endpoints included the proportion of patients with HbA1c ≤6.5%, changes in fasting plasma glucose (FPG), postprandial 2-h glycemic profile, body weight, insulin, glucagon, GLP-1, and insulin sensitivity of β-cell function, as determined by the Homeostatic Model Assessment (HOMA) index; all variables were measured at Weeks 24 and 48. Plasma glucose, glucagon, insulin, and GLP-1 levels were measured before and after a standardized breakfast (70 g instant noodles; equivalent to 500 kcal). Patient safety was monitored throughout the study.
Measurements
At baseline, demographic and patient clinical characteristics were obtained, including body weight, body mass index (BMI), HbA1c, FPG, 2-h postprandial glucose (2-h PPG), insulin and glucagon levels, insulin resistance (HOMA-IR), and β-cell function (HOMA-β). Active GLP-1 levels, that is GLP-1(7-36) and GLP-1 (7-37) levels, were determined using a commercially available radioimmunoassay kit (EMD Millipore, St Charles, MO, USA). Insulin and glucagon levels were determined using the area under the curve (AUC). Information regarding patient characteristics and biochemical measurements was also collected at Weeks 24 and 48.
The HOMA-IR and HOMA-β assessments were made using the following equations:
where FINS is fasting insulin (in mIU/L) and FPG was measured in mmol/L.
Distribution of patients according to changes in GLP-1
The total patient population was stratified by tertiles of changes in GLP-1 at 24 and 48 weeks as low (<45 and <101.4 pmol/mL per min, respectively), medium (45-2144 and 101.4-2310.75 pmol/mL per min, respectively), and high (>2144 and >2310.75 pmol/mL per min, respectively) ΔGLP-1 groups. Similarly, patients in the acarbose-and metformin-treated groups were stratified in ΔGLP-1 groups at 24 and 48 weeks. In the acarbose-treated groups, the ΔGLP-1 groups at 24 and 48 weeks were as follows: low, <32 and < −12.9 pmol/ mL per min, respectively; medium, 32-2054 and from −12.9 to 2257.05 pmol/mL per min, respectively; and high, >2054 and >2257.05 pmol/mL per min, respectively. The ΔGLP-1 groups in the metformin-treated patients at 24 and 48 weeks were: low, <72 and <287.55 pmol/mL per min, respectively; medium 72-2208 and 287.55-2406.9 pmol/mL per min, respectively; and high, >2208 and >2406.9 pmol/mL per min, respectively.
Statistical analysis
In the present post hoc analysis of data from the MARCH study, 12 associations between changes in GLP-1 levels at Weeks 24 and 48 and weight loss and changes in other clinical variables following treatment with acarbose or metformin were evaluated descriptively. Continuous variables with normal distribution are presented as the mean AE SD, and one-way analysis of variance (ANOVA) was used to compare differences between different patient groups stratified according to ΔGLP-1. Continuous variables that were not normally distributed are presented as median values with the interquartile range (IQR) and were compared using Kruskal-Wallis tests. Categorical variables are presented as counts and percentages, and the significance of difference between ΔGLP-1 groups were compared using Chisquared tests.
Multivariate linear regression analysis was used to assess which factors were associated with weight loss. The following clinically relevant factors were included in the linear regression model: age, gender, BMI, and ΔGLP-1. The study focused on only a few variables that were considered clinically important. Statistical analyses were performed using SAS version 9.1.3 (SAS Institute, Cary, NC, USA). Two-sided P < 0.05 was considered significant.
Results
Changes in clinical characteristics with greater ΔGLP-1 after 24 weeks treatment
In general, changes in clinical characteristics were similar across the ΔGLP-1 subgroups at Week 24 for the entire study population, as well as for the acarbose-and metformin-treated groups separately (Table 1) . For the entire population, changes in weight and BMI were significantly different across the ΔGLP-1 subgroups at Week 24 (P ≤ 0.036), with increasing ΔGLP-1 levels associated with greater losses in weight and BMI. For patients treated with acarbose, greater changes in ΔGLP-1 levels were associated with a greater reduction in weight, BMI, and FPG (P ≤ 0.024; Table 1 ). In the metformin-treated group, greater changes in GLP-1 levels after 24 weeks treatment were associated with a reduction in 2-h PPG (P = 0.009; Table 1 ).
Changes in clinical characteristics with greater ΔGLP-1 after 48 weeks treatment
Across the entire MARCH patient population, changes in the AUC for glucagon at 48 weeks were significantly different across the ΔGLP-1 subgroups (P = 0.04); greater changes in ΔGLP-1 levels were associated with greater decreases in the AUC for glucagon (Table 2 ). In the acarbose-treated group, medium ΔGLP-1 was associated with significantly greater reductions in BMI compared with the other ΔGLP-1 subgroups (P = 0.049; Table 2 ). No significant differences were found across the ΔGLP-1 subgroups in patients treated with metformin (P > 0.05; Table 2 ).
Multivariate linear regression analysis
Multivariate linear regression analysis was performed to determine which clinical parameters may affect weight loss in the total population and in patients treated with At Week 24, gender, BMI, and medium ΔGLP-1 were all significantly associated with weight reduction in the total patient population (P ≤ 0.0401). Body mass index and high ΔGLP-1 in the acarbose-treated group (P ≤ 0.0225) and BMI in the metformin-treated group (P < 0.001) were significantly associated with weight loss (Table 3) .
At Week 48, gender and BMI were significantly associated with weight reduction in the total patient population (P ≤ 0.0011). Gender and BMI in the acarbosetreated group (P ≤ 0.021) and age, gender, and BMI in the metformin-treated group (P ≤ 0.0485) were significantly associated with weight loss (Table 4) .
Differences in bodyweight between the education + run-in period and the beginning of the study
Prior to the start of the study, all patients participated in a 4-week education + run-in period and received instructions on lifestyles (diet, exercise). Although significant body weight loss was found in both the acarbose-and metformin-treated groups after the run-in period (P < 0.001), no significant differences were found between the two groups before or after the 4-week education (P > 0.05 for all; Table 5 ).
Discussion
The present descriptive study performed a subanalysis of data from the MARCH study to evaluate whether changes in GLP-1 levels in patients with T2D treated with acarbose or metformin for 48 weeks were associated with weight reduction. The study also assessed Changes in glucagon-like peptide-1 (ΔGLP-1) levels were stratified as follows. For the total population: low, <101.4 pmol/mL per min; medium, 101.4-2310.75 pmol/mL per min; and high, >2310.75 pmol/mL per min. For acarbose-treated patients: low, less than −12.9 pmol/mL per min; medium, from −12.9 to 2257.05pmol/mL per min; and high, >2257.05 pmol/mL per min. For metformin-treated patients: low, <287.55 pmol/ mL per min; medium, 287.55-2406.9 pmol/mL per min; and high, >2406.9 pmol/mL per min. BMI, body mass index.
which patient characteristics affected weight loss.
Greater changes in GLP-1 were associated with greater weight loss and reductions in BMI in the total study population after 24 weeks treatment and greater reductions in the AUC for glucagon after 48 weeks treatment. Greater changes in GLP-1 were also associated with greater decreases in weight and BMI at Week 24 in the acarbose-treated group. The biggest decrease in BMI at Week 48 in the acarbose-treated group was seen in patients with medium ΔGLP-1. High ΔGLP-1 was not associated with weight loss at Week 24 in patients treated with metformin. In addition, changes in GLP-1 were predictive of weight reduction, as evaluated by multivariate regression analysis. After 24 and 48 weeks treatment with metformin or acarbose, changes in HbA1c were independent of changes from baseline in GLP-1, consistent with the action of these drugs in treating T2D. Both acarbose and metformin have been shown to promote weight reduction in patients with T2D. [5] [6] [7] [8] [9] [10] [11] [12] [23] [24] [25] [26] [27] The effect of acarbose on weight may be a class effect, because several studies have found that AGIs either reduce weight by 0.5-0.9 kg or are weight neutral. [5] [6] [7] [8] [9] [10] [11] A recent systematic review and metaanalysis also found that the use of metformin or the AGIs acarbose, miglitol, or liraglutide was associated with weight loss of 1.1, 0.4, 0.7, and 1.7 kg, respectively. 9 In addition, a study that assessed the tolerability and safety of acarbose in patients with diabetes found that acarbose, as monotherapy or in combination with insulin or sulfonylureas, reduced the mean body weight up to 0.9 kg after 5 years treatment. 10 A multicenter randomized study performed in China that compared the efficacy and tolerability of 24 weeks treatment with vildagliptin or acarbose monotherapy in patients with treatment-naïve T2D found that body weight decreased in acarbosetreated patients (mean [AE SEM] -1.7 AE 0.2 kg; P < 0.001), but not in patients treated with vildagliptin (−0.4 AE 0.1 kg).
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Differences between treatment groups in the factors associated with weight loss and in the findings at Weeks 24 and 48 in the present study may reflect, in part, differences in the mechanism of action of the two drugs. The primary mechanism by which metformin leads to weight loss is by decreasing food consumption. 24 Less is known as to how acarbose promotes weight loss. Acarbose may increase GLP-1 levels by blocking the breakdown of disaccharides through inhibition of α-glucosidase present in the brush border of mucosal epithelial cells of the small intestine. Consequently, large amounts of undigested carbohydrates reach the lower portion of the small intestine, which is rich in L cells that produce GLP-1. The high levels of undigested carbohydrates stimulate GLP-1 secretion and reduce gastric inhibitory polypeptide (GIP) secretion from K cells, which also enhances GLP-1 secretion from L cells. 28, 29 Miglitol, another AGI, has been shown to activate duodenal enterochromaffin cells, possibly via sodium-glucose cotransporter 3 (SGLT3), and consequently potentiate GLP-1 secretion through the parasympathetic nervous system. 30 Complex cross-talk and trafficking of the GLP-1 receptor, insulin regulation, and other related receptors are involved in cellular signaling events and weight control. [31] [32] [33] The results of the present study suggest that metformin and acarbose act differently via GLP-1 to reduce weight. It is well established that higher GLP-1 levels can promote weight reduction. [34] [35] [36] [37] [38] Glucagon-like peptide-1 is a proglucagon-derived peptide that improves glucose homeostasis by enhancing glucose-dependent insulin secretion, inhibiting inappropriately high levels of postprandial glucagon secretion, delaying gastric emptying, and reducing food intake. [13] [14] [15] [16] Increasing GLP-1 levels, which subsequently enhance glucose-dependent insulin secretion, inhibit glucagon secretion and delay gastric emptying. 13, 14, [39] [40] [41] [42] The findings of the present study suggest that acarbose may reduce weight by increasing GLP-1 levels, and this could explain, at least in part, why in the MARCH study acarbose treatment reduced weight to a greater extent than metformin. 12 The findings of the present study are consistent with those of a prior study that found acarbose was associated with significantly increased levels of both fasting and postprandial GLP-1 after 24 weeks treatment in patients newly diagnosed with T2D. 43 Other studies have also reported that postprandial GLP-1 levels increase after acarbose treatment in both normal and diabetic patients. [44] [45] [46] Increasing evidence from multiple studies indicates that GLP-1 acts on the vasculature, liver, myocardium, β-cells, and brain to promote the structural and functional integrity of these organs. [47] [48] [49] [50] Hence, acarbose treatment may affect multiple biological processes in addition to glucose improvement through upregulated GLP-1 levels.
In the present study, gender, BMI, and changes in GLP-1 levels from baseline were predictive of weight loss in the entire patient population after 24 weeks treatment. Body mass index and change in GLP-1 levels from baseline were also associated with weight loss in the acarbose-treated groups at Week 24. At Week 48, gender and BMI were predictive of weight loss across the entire population and each treatment group. The importance of gender and BMI on weight loss has been observed in prior studies. [51] [52] [53] [54] Other factors that have been implicated as important in predicting weight loss include baseline fatness, physiological and behavioral factors, physical activity, socioeconomic status, smoking status, and age at onset of obesity. [53] [54] [55] [56] Overall, findings with regard to parameters that may be useful in predicting weight loss have been inconsistent across studies, possibly indicating differences in study designs and the large number of physical, behavioral, genetic, and social variables that affect weight.
It is not clear why the effect of acarbose on GLP-1 in the present study was not maintained from 24 to 48 weeks of treatment. A trend for increased GLP-1 levels with acarbose treatment was observed at Week 48. The lack of a significant increase in GLP-1 levels at Week 48 may reflect the small sample size of this subgroup or that this relationship is affected by other biological or behavioral parameters that changed during the extended treatment. Glucagon-like peptide-1 levels increased from Week 0 to Week 24, but the change in levels between Week 24 and Week 48 was not significant. 12 It is possible that the initial effect on weight reflects the change in GLP-1 levels and that once the levels plateaued, little additional weight was lost. It is unlikely that the difference between Week 24 and Week 48 is due to add-on treatment with insulin secretagogs, because only five patients in the acarbose-treated group and three in the metformin-treated group received insulin secretagogs after Week 24. In addition, all patients received a 4-week lifestyle modification intervention prior to drug treatment, and the effect of this intervention on weight may have been greater in the first 24 weeks of the study compared with the later part of the study. However, the differences between treatments with regard to weight suggest that lifestyle modification was not the only reason for weight loss. Larger studies are required to further investigate the effect of acarbose on GLP-1 levels in patients with T2D.
The present study has certain limitations. First, it was a descriptive analysis of the MARCH study. In addition, the study investigated the role of only a selected group of variables in weight loss using multivariate analysis. It is possible that other parameters or factors also affect weight loss. For example, the effect of acarbose on weight loss is more pronounced in the Asian population compared with European and North American populations. 57 Only Chinese patients were enrolled in the MARCH study. Hence, it is unclear how the findings, with regard to the effects of GLP-1 levels on weight loss and insulin regulation, relate to other ethnic groups and geographical regions. In addition, although patient weight was tracked throughout the study, including at the end of the 4-week education + run-in period prior to the start of the study, we did not determine to what extent any lifestyle modifications adopted during the education period may have contributed to weight loss.
In summary, the present study found that acarbose treatment was associated with a significant increase in GLP-1 levels. The upregulation of GLP-1 may play an important role in weight reduction observed with acarbose treatment in the MARCH study. The present was a novel study to investigate the effects of acarbose and metformin after 24 and 48 weeks treatment on weight loss and GLP-1 levels in patients newly diagnosed with T2D. In addition, the present study reports the effects of acarbose on weight control through GLP-1. Acarbose has become one of the first-line drugs in treating patients with T2D, based on the MARCH study. The results of the present study suggest that acarbose combined with dipeptidyl peptidase 4 inhibitors may help with weight control in patients newly diagnosed with T2D. The findings may serve as the basis for drug development in the future to treat T2D.
